Valuation Gedeon Richter LUXEMBOURG S.E.

Stocks

End-of-day quote LUXEMBOURG S.E. 2026-10-22			5-day change	1st Jan Change
39.20 ^USD	+0.51%		0.00%	+29.80%

10-14	Gedeon Richter Plc. Receives Fda Submission Acceptance of New Drug Application for Fylrevy® in the U.S	CI
09-18	EU Medicines Agency Panel Issues Positive Opinion on Gedeon Richter's Arthritis Drug	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	1,619,625	1,542,290	1,627,029	1,893,161	1,799,226	2,402,084	-	-
Change	-	-4.77%	5.49%	16.36%	-4.96%	33.51%	-	-
Enterprise Value (EV) ¹	1,559,769	1,395,557	1,546,536	1,782,343	1,588,618	2,139,608	1,992,072	1,865,104
Change	-	-10.53%	10.82%	15.25%	-10.87%	34.68%	-6.9%	-6.37%
P/E	11.6x	9.94x	10.2x	7.96x	7.76x	9.69x	8.29x	7.67x
PBR	1.78x	1.47x	1.44x	1.49x	1.31x	1.6x	1.45x	1.31x
PEG	-	0.9x	3.41x	0.2x	-2.82x	1.4x	0.5x	0.95x
Capitalization / Revenue	2.57x	1.92x	2.02x	2.21x	1.94x	2.52x	2.35x	2.2x
EV / Revenue	2.47x	1.74x	1.92x	2.08x	1.71x	2.25x	1.95x	1.71x
EV / EBITDA	8.86x	7.1x	6.43x	5.74x	4.5x	5.82x	5.03x	4.39x
EV / EBIT	11.5x	9.09x	8.15x	6.82x	5.42x	7.08x	5.98x	5.19x
EV / FCF	-460x	12.3x	17.9x	8.26x	7.56x	9.47x	8.69x	7.54x
FCF Yield	-0.22%	8.12%	5.6%	12.1%	13.2%	10.6%	11.5%	13.3%
Dividend per Share ²	225	390	-	-	-	603.6	677	738.7
Rate of return	2.58%	4.7%	-	-	-	4.58%	5.14%	5.61%
EPS ²	751	835	860	1,307	1,271	1,359	1,589	1,718
Distribution rate	30%	46.7%	-	-	-	44.4%	42.6%	43%
Net sales ¹	630,595	802,755	805,158	857,545	928,962	951,368	1,020,834	1,093,689
EBITDA ¹	176,123	196,480	240,625	310,678	353,314	367,576	396,366	425,015
EBIT ¹	135,832	153,555	189,817	261,157	292,851	302,220	332,887	359,032
Net income ¹	139,626	155,581	158,850	239,244	232,335	254,304	290,549	314,929
Net Debt ¹	-59,856	-146,733	-80,493	-110,818	-210,608	-262,476	-410,012	-536,980
Reference price ²	8,725.00	8,300.00	8,750.00	10,400.00	9,865.00	13,170.00	13,170.00	13,170.00
Nbr of stocks (in thousands)	185,630	185,818	185,946	182,035	182,385	182,391	-	-
Announcement Date	3/2/22	2/28/23	2/29/24	4/7/25	2/27/26	-	-	-

¹HUF in Million²HUF

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	37.7x	13.43x	28.51x	0.52%	1,165B
JOHNSON & JOHNSON	39.17x	6.59x	18.54x	1.99%	645B
ABBVIE INC.	36.4x	8.37x	17.27x	2.41%	504B
ROCHE HOLDING AG	20.97x	5.15x	12.78x	2.55%	380B
MERCK & CO., INC.	107.33x	5.99x	25.72x	2.31%	363B
NOVARTIS AG	21.95x	5.71x	14.04x	2.79%	297B
ASTRAZENECA PLC	22.67x	4.58x	13.09x	1.93%	269B
AMGEN INC.	28.38x	7.14x	12.79x	2.26%	237B
GILEAD SCIENCES, INC.	-45.82x	7.02x	27.23x	2.1%	195B
Average	29.86x	7.11x	18.89x	2.1%	450.61B
Weighted average by Cap.	35.73x	8.44x	20.74x	1.78%